The anti-tumor effect of oncolytic virus therapy is significantly greater in mice when the virus is genetically modified to express a junction opening (JO) protein, which helps the cancer-killing agent better penetrate solid tumors, showed a new study.
Roma Yumul, Maximilian Richter, and coauthors, University of Washington, Compliment Corp., and PAI Life Sciences Inc. (Seattle, WA), Chinese Center for Disease Control and Prevention (Beijing, PR China), and BRIM Biotechnology Inc. (Taipei, Taiwan), explain how the tight junctions between malignant epithelial cells allow solid tumors to resist the effects of anticancer drugs including oncolytic viruses.
Scientists Find Method to Make Complex Anticancer Compound
At The Scripps Research Institute (TSRI), scientists have achieved the first efficient chemical synthesis of ingenol, a highly complex, plant-derived compound that has long been of interest
Advertisement
‘Enhancing the anticancer effect inside the tumors using an epithelial junction opener increases the success rate in solid tumors, which are hard to treat.
’
Tweet it Now
In the article "Epithelial Junction Opener Improves Oncolytic Adenovirus Therapy in Mouse Tumor Models," the researchers demonstrate that administering the JO protein together with an oncolytic adenovirus into the tumors of mice, or engineering the virus to produce and secrete the JO protein inside tumor cells, greatly enhances the antitumor effect compared to treatment with unmodified virus.
This article is part of a Festschrift in honor of George Stamatoyannopoulous, MD, DrSci, Professor of Medicine and Genome Sciences, and Director, Markey Molecular Medicine Center, University of Washington, Seattle.
![Anticancer Drug Restores Hearing in People With Neurofibromatosis]( "Anticancer Drug Restores Hearing in People With Neurofibromatosis")
One in 25,000 people is born with neurofibromatosis type 2, a hereditary tumor syndrome in which virtually everyone progresses to deafness because of vestibular schwannomas.
"Oncolytic adenoviruses are rapidly making a big impact in therapy for many different cancers," says Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Medical School, Worcester, MA. "The concept of enhancing the penetration of such viruses into tumors using an epithelial junction opener promises to improve the success rate of such therapies in bulkier solid tumors, which are often very hard to treat."
The article is published in the a peer-reviewed journal Human Gene Therapy.
Source: Eurekalert
Anticancer Drug Restores Hearing in People With Neurofibromatosis
One in 25,000 people is born with neurofibromatosis type 2, a hereditary tumor syndrome in which virtually everyone progresses to deafness because of vestibular schwannomas.
Advertisement
"Oncolytic adenoviruses are rapidly making a big impact in therapy for many different cancers," says Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Medical School, Worcester, MA. "The concept of enhancing the penetration of such viruses into tumors using an epithelial junction opener promises to improve the success rate of such therapies in bulkier solid tumors, which are often very hard to treat."
The article is published in the a peer-reviewed journal Human Gene Therapy.
Source: Eurekalert
Target of Anticancer Drugs Have Broader Functions
Histone deacetylases (HDACs) are the drugs that inhibit the activity of enzymes. They are being widely developed for treating cancer and other diseases, with two already on the market.
Advertisement
 Anticancer Drug Mechanism Understood BetterThe subtle effect that prescription drug Taxol has inside cells, which makes it one of the most widely used anticancer drugs in the world has now been understood by a team of researchers | Advertisement
|
Advertisement
Recommended Reading
Latest Cancer News
The mechanism by which the kinases cause inflammation has been discovered by scientists.
Pancreatic cancer cases are on the rise. The biomarker approach could reduce the chance of developing pancreatic cancer.
New combination of medications trametinib and entinostat were found to decrease lung cancer in mice.
Combination treatment with TALZENNA and XTANDI was found to benefit prostate cancer patients, revealed study.
In leukemia patients, reduced amounts of dietary vitamin A is associated with a higher risk and severity of pancreatitis.